Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

OB GYN new masthead 1

August 1, 2021

View Archives Issues

  • Mifepristone as an Adjunct to Misoprostol for Pregnancy Termination

    In this prospective, double-blind, randomized, placebo-controlled trial, pretreatment with 200 mg of mifepristone 24 to 48 hours before labor induction using misoprostol significantly reduced time to delivery among demised fetuses between 14 and 28 weeks of gestation. Maternal complications were equivalent in both groups.

  • BSO at Benign Hysterectomy: What Should We Be Recommending?

    In this population-based retrospective cohort study, among 44,549 adult women undergoing hysterectomy in Ontario, Canada, there was marked variation between surgeons in bilateral salpingo-oophorectomy (BSO) rates after controlling for patient age and other factors. Approximately 41% of patients had no indication for the bilateral salpingo-oophorectomy in their records.

  • Standard-Dose vs. High-Dose Oxytocin for Labor Augmentation

    In this randomized clinical trial of standard-dose vs. high-dose oxytocin regimens for labor augmentation among 1,003 nulliparous women, the primary outcome (cesarean delivery) was similar between the two groups. However, secondary outcomes were lower, labor duration was shorter, and umbilical artery acidemia occurred less frequently.

  • Disease Severity and Perinatal Outcomes of Pregnant Patients with COVID-19

    In this observational cohort study of patients with singleton gestation and positive coronavirus test, patients with severe or critical disease were at risk for perinatal complications compared to those who were asymptomatic. Patients classified with mild or moderate disease were not shown to have an increased risk compared to asymptomatic positive patients.